T-Bren clinical trials
T-Bren is named as an intervention in 21 current clinical trials in our China and USA registers. 15 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sichuan Baili Pharmaceutical Co., Ltd (19). The most-studied condition is HER2-positive Breast Cancer.
Patient leaflets for T-Bren
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of T-Bren
21 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with T-Bren
26 conditionsAll 26 conditions
| Condition (as registered) | Trials |
|---|---|
| HER2-positive Breast Cancer | 5 |
| Breast Cancer | 2 |
| Non-squamous Non-small Cell Lung Cancer | 2 |
| Urothelial Cancer | 1 |
| Metastatic Urothelial Cancer | 1 |
| Bladder Cancer | 1 |
| Bladder Cancer (BC) | 1 |
| Endometrial Cancer | 1 |
| Cervical Cancer | 1 |
| Ovarian Cancer | 1 |
| Urothelial Carcinoma | 1 |
| Gynecological Malignancies | 1 |
| Locally Advanced or Metastatic Solid Tumor | 1 |
| HER2-low Breast Cancer | 1 |
| Colorectal Cancer | 1 |
| Biliary Tract Cancer | 1 |
| Non-small Cell Lung Cancer | 1 |
| Epithelial Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Primary Peritoneal Cancer | 1 |
| Gastric Adenocarcinoma | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Locally Advanced or Metastatic Digestive Tract Tumors | 1 |
| Other Solid Tumors | 1 |
| HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | 1 |
| Her2-positive/Low-expression Urinary and Digestive Tract Tumors | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd | 19 |
| SystImmune Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 19 | 13 |
| Clinical trials in USA | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about T-Bren trials
How many clinical trials are testing T-Bren?
21 current trials in our China and USA registers name T-Bren (also registered as BL-M07D1) as a drug or biological intervention, as of the registry sync on 14 October 2026. Completed and withdrawn studies are not counted.
Are T-Bren trials recruiting patients?
Yes. 15 of the 21 trials are recruiting: 13 with sites in China and 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors T-Bren clinical trials?
Sichuan Baili Pharmaceutical Co., Ltd (19) and SystImmune Inc (2). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how T-Bren works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how T-Bren works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists T-Bren (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 14 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.